Mathew A, et al. – Analysts ascertain the prevalence and determinants of end–of–life chemotherapy use in patients with metastatic breast cancer. Prevalence of the utilization of end–of–life chemotherapy in this cohort was higher than previously depicted. More end–of–life chemotherapy was utilized in younger women and those with greater disease burden. Earlier initiation of end–of–life discussions may be targeted to such patients.